Compare Linde PLC (LIN) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Linde PLC vs BIO-TECHNE Corp — how do they compare? Linde PLC trades at $493.69 (market cap $227.01B), while BIO-TECHNE Corp trades at $72.05 (market cap $11.24B). The key difference: Linde PLC is far larger — about 20.2× BIO-TECHNE Corp's market cap, and Linde PLC pays the higher dividend (1.3%). Which is the better fit depends on your goals.
| LIN | TECH | |
|---|---|---|
Market Cap | $227.01B | $11.24B |
Sector | Basic Materials | Health |
52-Week High | $546.64 | $72.29 |
52-Week Low | $389.38 | $43.31 |
Enterprise Value | $250.13B | $11.32B |
Dividend Yield | 1.3% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Linde (LIN) trades at $489.98, showing minimal daily change. The stock exhibits strong fundamentals with consistent earnings beats, a 20.43% net income margin, and robust cash flow. However, technical indicators signal a bearish short-term trend, with the price near the pivot point of $490. Recent news highlights sustainability leadership and Q1 2026 EPS growth of 10% year-over-year, though a DCF analysis from GuruFocus on June 1, 2026, suggested potential overvaluation at a $327 fair value.
The investment outlook is supported by solid profitability and a bullish analyst consensus with a $553.60 price target, but risks include elevated valuation multiples and increasing debt-to-asset ratios. The stock's near-term direction may hinge on Q3 2026 earnings versus the $4.53 estimate, with technical resistance at $493 posing a challenge to upside momentum.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
